Previous 10 | Next 10 |
BOSTON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, go...
BOSTON, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gov...
Investment Thesis Reviewing Paratek Pharmaceuticals ( PRTK ) - a commercial-stage biopharmaceutical company with 2 approved antibiotic products, Nuzyra and Seysara - I am inclined to believe that there is a reasonably strong case for investment. The antibiotics market offers unfavourable m...
Gainers: Yield10 Bioscience (NASDAQ: YTEN ) +60% . More news on: Yield10 Bioscience, Inc., Renren Inc., Virtusa Corporation, Stocks on the move, , Read more ...
BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, go...
Paratek Pharmaceuticals, Inc. (PRTK) Q2 2020 Earnings Conference Call August 10, 2020 08:30 AM ET Company Participants Ben Strain - Vice President, Investor Relations and Corporate Communications Evan Loh - Chief Executive Officer Adam Woodrow - President and Chief Commercial Off...
The following slide deck was published by Paratek Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings Read more ...
Paratek Pharmaceuticals (NASDAQ: PRTK ) : Q2 GAAP EPS of -$0.53 misses by $0.47 . Revenue of $9.3M (+353.7% Y/Y) misses by $28.73M . Press Release More news on: Paratek Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
-- Paratek Raises Full Year 2020 Revenue Guidance; Total Revenue guidance expected to be Between $78 and $83 Million Driven by Strong NUZYRA Net Revenue -- Company Lowering 2020 R&D and SG&A Expense Guidance...
BOSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, go...
News, Short Squeeze, Breakout and More Instantly...
Paratek Pharmaceuticals Inc. Company Name:
PRTK Stock Symbol:
NASDAQ Market:
Paratek Pharmaceuticals Inc. Website:
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Paratek Pharmaceuticals Inc. (PRTK) is expected to report $-0.25 for Q3 2023
BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military ...